Humacyte (HUMA) announced the presentation of positive results from the V007 Phase 3 clinical trial of the acellular tissue engineered vessel, ATEV, in arteriovenous, AV, access for patients with end-stage renal disease at the American Society of Nephrology’s, ASN, Kidney Week 2024, the premier nephrology meeting, in San Diego. In the Phase 3 trial, the ATEV demonstrated superior function and patency at six and 12 months compared to autogenous fistula, which is the current standard of care for hemodialysis patients, and also showed superior function and patency in female, obese and diabetic patients, each of which is a high-need subgroup with historically poor outcomes with AV fistula procedures. The late-breaking podium presentation, titled “Prospective Randomized Trial of Humacyte’s Acellular Tissue Engineered Vessel Versus Autologous Arteriovenous Fistula for Hemodialysis Access,” was presented on Saturday, October 26, 2024.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Humacyte to host KOL event on he use of ATEV for AV access in hemodialysis
- Hertz Global Holdings call volume above normal and directionally bullish
- Unusually active option classes on open October 18th
- Humacyte issues raised in 483 appear ‘fixable,’ says BTIG
- Humacyte facility inspection likely not root cause of BLA delay, says TD Cowen